Meeting Banner
Abstract #1526

Surveillance in Germline TP53 Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging

Kate Moodie1, Nick Ferris2, David Thomas3, Mandy Ballinger3, Emma Galligan1, Marion Harris4, Paul James1, Gillian Mitchell1, Eveline Niedermayr1, Bimal Parameswaran5, Deborah Schofield3, Sue Shanley6, Alison Trainer1, and Mary-Anne Young1

1Peter MacCallum Cancer Centre, Melbourne, Australia, 2Monash Imaging, Monash Health, Melbourne, Australia, 3Garvan Institute of Medical Research, Sydney, Australia, 4Monash Health, Melbourne, Australia, 5Eastern Health, Melbourne, Australia, 6Peter MacCallum Cancer Institute, Melbourne, Australia

Germline TP53 mutations are associated with Li-Fraumeni syndrome (LFS). Mutation carriers ascertained on family history have an extremely high lifetime risk of cancers arising from one or more of many possible sites. There is no established screening strategy for early detection and treatment of these cancers. Herein, we report preliminary data from a prospective study of a whole-body screening program that includes whole-body. Five new malignancies (3 de novo, 2 recurrent) have been identified in five of the first 30 participants, suggesting potentially significant benefits from screening in this population.

This abstract and the presentation materials are available to members only; a login is required.

Join Here